These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2482052)

  • 1. HIV antibodies and vaccine design.
    Bolognesi DP
    AIDS; 1989; 3 Suppl 1():S111-8. PubMed ID: 2482052
    [No Abstract]   [Full Text] [Related]  

  • 2. AIDS 1989. Vaccines and immunology: overview.
    Laurence J; Schild GC
    AIDS; 1989; 3 Suppl 1():S97-100. PubMed ID: 2514762
    [No Abstract]   [Full Text] [Related]  

  • 3. Immortalization of antigen selected B cells.
    Steenbakkers PG; van Wezenbeek PM; Olijve W
    J Immunol Methods; 1993 Jul; 163(1):33-40. PubMed ID: 7687638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immunity to the human immunodeficiency virus.
    Weber J
    Curr Opin Immunol; 1989-1990 Feb; 2(3):420-3. PubMed ID: 2483884
    [No Abstract]   [Full Text] [Related]  

  • 5. How does the HIV escape cytotoxic T cell immunity?
    Phillips RE; McMichael AJ
    Chem Immunol; 1993; 56():150-64. PubMed ID: 7680867
    [No Abstract]   [Full Text] [Related]  

  • 6. [AIDS vaccines: an enigma in vaccine development].
    Dorner F; Barrett N
    Wien Klin Wochenschr; 1990 Jan; 102(2):51-8. PubMed ID: 1689919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design.
    Cagigi A; Nilsson A; De Milito A; Chiodi F
    Vaccine; 2008 Jun; 26(24):3016-25. PubMed ID: 18164520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC-restricted cytotoxicity against HIV.
    Autran B; Plata F; Debre P
    J Acquir Immune Defic Syndr (1988); 1991; 4(4):361-7. PubMed ID: 1706768
    [No Abstract]   [Full Text] [Related]  

  • 9. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
    Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
    Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV vaccines. Magic of the occult?
    Montefiori D; Moore JP
    Science; 1999 Jan; 283(5400):336-7. PubMed ID: 9925493
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30.
    Boucher CA; Krone WJ; Goudsmit J; Meloen RH; Naylor PH; Goldstein AL; Sun DK; Sarin PS
    J Clin Lab Anal; 1990; 4(1):43-7. PubMed ID: 1690277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailored immunogens for rationally designed antibody-based HIV-1 vaccines.
    Mouquet H
    Trends Immunol; 2015 Aug; 36(8):437-9. PubMed ID: 26169255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunocytochemical determination of antigen and epitope specificity of HIV-1-specific B cells in lymph-node biopsies from HIV-1-infected individuals.
    Laman JD; Rácz P; Tenner-Rácz K; Klasmeier M; Fasbender MJ; Neelen C; Zegers ND; Dietrich M; Boersma WJ; Claassen E
    AIDS; 1991 Mar; 5(3):255-62. PubMed ID: 1711861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1.
    Ding J; Lu Y; Chen Y
    FEMS Immunol Med Microbiol; 2000 Oct; 29(2):123-7. PubMed ID: 11024351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and specificity of broadly neutralizing antibodies against HIV.
    McCoy LE; Burton DR
    Immunol Rev; 2017 Jan; 275(1):11-20. PubMed ID: 28133814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and opportunities for development of an AIDS vaccine.
    Nabel GJ
    Nature; 2001 Apr; 410(6831):1002-7. PubMed ID: 11309631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV Broadly Neutralizing Antibodies: VRC01 and Beyond.
    Wu X
    Adv Exp Med Biol; 2018; 1075():53-72. PubMed ID: 30030789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1-specific B cell activation. A major constituent of spontaneous B cell activation during HIV-1 infection.
    Amadori A; Zamarchi R; Ciminale V; Del Mistro A; Siervo S; Alberti A; Colombatti M; Chieco-Bianchi L
    J Immunol; 1989 Oct; 143(7):2146-52. PubMed ID: 2476498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictions of linear T-cell and B-cell epitopes in proteins encoded by HIV-1, HIV-2 and SIVMAC and the conservation of these sites between strains.
    Zvelebil MJ; Sternberg MJ; Cookson J; Coates AR
    FEBS Lett; 1988 Dec; 242(1):9-21. PubMed ID: 2462515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994-1995.
    Berzofsky JA; Berkower IJ
    AIDS; 1995; 9 Suppl A():S143-57. PubMed ID: 8819581
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.